^
    2ms
    Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (clinicaltrials.gov)
    P2, N=34, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2027 --> May 2026
    Trial completion • Trial completion date
    |
    apalutamide
    2ms
    Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial (clinicaltrials.gov)
    P3, N=586, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test
    |
    apalutamide
    2ms
    Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models. (PubMed, Mol Imaging Biol)
    Direct AR antagonism enhances functional PSMA availability and increases short-term uptake of PSMA-targeted radioligands in AR-positive prostate cancer models. These findings provide mechanistic support for AR-mediated modulation of PSMA-targeted radioligand delivery and warrant further translational investigation.
    Preclinical • Journal
    |
    AR (Androgen receptor) • FOLH1 (Folate hydrolase 1)
    |
    AR positive • FOLH1 expression
    |
    enzalutamide • abiraterone acetate • apalutamide
    2ms
    SCALP1: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (clinicaltrials.gov)
    P3, N=703, Completed, Cassiopea SpA | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2026
    Trial completion • Trial completion date
    2ms
    The State of Imidazolone as an Evolving Pharmacophore: Current Progress and Clinical Significance in Oncology and AMR. (PubMed, ACS Omega)
    Nevertheless, the significant therapeutic and clinical efficacy of imidazolone-bearing drugs, such as Nilutamide, Irbesartan, and Leucettinib-21, in anticancer, antihypertensive, and neurotherapeutic applications has stimulated increasing interest in imidazolone chemistry and its medicinal potential. The convergence of in silico predictions with experimental findings offers valuable guidance for the rational development of imidazolone-based therapeutics. Overall, this review emphasizes imidazolones as promising scaffolds with significant potential for future drug discovery and development.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2)
    |
    nilutamide
    3ms
    Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). (2025-523672-23-00)
    P1/2, N=42, Not yet recruiting, UroTrials GmbH, AIO-Studien gGmbH
    New P1/2 trial
    3ms
    PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=692, Active, not recruiting, Janssen Pharmaceutica N.V., Belgium | Trial completion date: Aug 2029 --> Sep 2031
    Trial completion date
    |
    apalutamide • triptorelin • goserelin acetate
    3ms
    Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Trial completion date
    4ms
    Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study. (PubMed, Cancer Sci)
    This study demonstrated that baseline ctDNA predicts prognosis of Japanese patients with mCSPC receiving apalutamide with ADT and identified potential genetic predictors for treatment-related skin rash. Trial Registration: ClinicalTrials.gov identifier: jRCTs071200040.
    Journal
    |
    AR (Androgen receptor)
    |
    apalutamide
    4ms
    Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Feb 2027 --> Mar 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Oncotype DX Genomic Prostate Score® Assay
    |
    abiraterone acetate • prednisone • apalutamide
    4ms
    Single center, single-arm, Retrospective study on neoadjuvant Tx of HR LPC with apalutamide (ChiCTR2600121368)
    P=N/A, N=40, THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY; THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY
    New trial
    |
    apalutamide
    4ms
    To evaluate the safety and efficacy of Apololitowereili Monoclonal Antibody combined with FLOT regimen in patients with locally advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma. (ChiCTR2600120362)
    P2, N=29, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • HER-2 negative
    |
    apalutamide